“The Diabetic Macular Edema Pipeline Insight report provides deep insights into emerging pipeline therapies for diabetic macular edema with an analysis of 60+ key players and 65+ key therapies”

DelveInsights’Diabetic Macular Edema Pipeline The Insights report provides a holistic view of the pipeline therapies for diabetic macular edema in pre-clinical and clinical development and growth prospects across the diabetic macular edema landscape.

Key Findings from the Diabetic Macular Edema Pipeline Report

• The Diabetic Macular Edema Pipeline report provides a comprehensive analysis of 50+ key players and 50+ key therapies.
• Of all the emerging therapies, late-stage products such as such as Faricimab, Beovu and KSI-301 have shown promising results and are expected to improve the dosing interval.
• The diabetic macular edema pipeline includes MS 553 (Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.), KSI 301 (Kodiak Sciences Inc.), Brolucizumab (Novartis Pharmaceuticals), ADVM-022 (Adverum Biotechnologies, Inc.), KVD001 (KalVista Pharmaceuticals), MYL-1701P ( Momenta Pharmaceuticals/Mylan), Faricimab (Roche) and othersand other.

Would you like more information about therapies for diabetic macular edema? https://www.delveinsight.com/sample-request/diabetic-macular-edema-pipeline-insight

Overview of diabetic macular edema

Diabetic macular edema (DME) is an eye condition that can occur in people with diabetes, both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Diabetic retinopathy is a condition that damages the blood vessels in the retina, leading to impaired vision. If left untreated, fluid can leak into the center of the macula called the fovea, the part of the eye where sharp, straight vision occurs. The fluid causes the macula to swell and blur. This condition is referred to as DME. It can occur at any stage of diabetes…